Deal●
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Western biopharma companies are increasingly turning to China to source drug innovation
- The shift comes as pharma's patent cliff draws closer
NSE close · Thu, 1 OctNifty 5022,421.95▼ 0.88%Nifty Bank54,450.75▼ 0.33%Midcap 10058,732.00▼ 1.01%Smallcap 25017,589.05▼ 1.18%India VIX14.46▲ 7.19%IT28,304.70▲ 2.17%Auto25,384.95▼ 3.46%Pharma26,311.55▼ 0.48%FMCG43,789.85▼ 1.61%Metal12,460.70▼ 2.35%Realty835.00▼ 1.46%Energy36,388.15▼ 0.68%PSU Bank7,937.80▼ 0.98%Financials24,556.10▼ 0.38%Media1,546.30▼ 2.33%Defence9,142.55▼ 1.45%Durables35,927.80▼ 1.91%Biggest movesMONEYVIEW▲ 58.5%MOLBIO▲ 15.6%THOMASCOTT▲ 12.3%AUGMONT▲ 10.0%HEROMOTORS▲ 10.0%VIVIANA▲ 10.0%LOKESHMACH▲ 9.5%ANAWIL▼ 11.0%
Topic
Pharma and healthcare▼ −30% net tone today
Nifty Pharma −0.48% vs Nifty −0.88% on Thu, 1 Oct- Granules India incorporated Triton Farmaceutica Do Brasil Ltda as a wholly owned subsidiary in Brazil
- Global Health acquired land in Ghaziabad for a planned Medanta hospital
- Maharashtra FDA cancelled Cipla Pharma’s Pune warehouse distribution licences over serious violations
Stories per day
527 Sept
3528 Sept
3829 Sept
3030 Sept
291 Oct
142 Oct
03 Oct
Deal●